-
In the ever changing world of clinical research, staying up to date with the latest guidelines and best practices is crucial. Our ICH E6(R3) Good Clinical Practice Training is designed for busy professionals who want to deepen their knowledge on GCP to help ensure they meet the highest standards of quality, safety, and compliance.
-
In March, 2025, the European Medicines Agency (EMA) released a “Reflection paper on use of real-world data (RWD) in non-interventional studies (NIS) to generate real-world evidence (RWE) for regulatory purposes” as a guidance for stakeholders on quality planning, conduct and analysis of NISs that intend to use RWD to generate RWE.
-
In November 2024, the US Food and Drug Administration (FDA) issued a warning letter to the sponsor as a result of a BioResearch Monitoring Program (BIMO) inspection which observed objectionable conditions. The warning letter cited two violations of the Title 21 CFR.
-
In December 2024, following the release of the 2024 revision of the Declaration of Helsinki (DoH), US Food and Drug Administration (FDA) staff shared the FDA’s perspective on what their role was in the development of the 2024 DoH and how it may impact FDA procedures. The DoH is intended to guide clinical research involving human participants that is often used as the foundation for other guidelines such as the International Council for Harmonisation (ICH) Good Clinical Practice (GCP).
-
Over time, the clinical trial industry has figured out how to coordinate onsite monitoring of a study patient’s electronic health record. This can be through certified copies (very laborious for sites) or increasingly often by providing temporary secure access to source documentation for a particular trial.
Purchase the recorded webinar here. Access to the recording is available for 10 days after purchase.
-
The Office for Human Research Protections (OHRP), released the 2020 edition of the International Compilation of Human Research Standards, which is available here. The Standards compile more than 1,000 laws, regulations, and guidelines from 133 countries. The Standards are applicable to stakeholders in clinical research globally, including sponsors, investigators, and Ethics Committees.
-
Myth: Source data needs to be redacted before it can be reviewed by a monitor for remote monitoring.
Answer: The question is, why would you redact when the patient gave authorization to use and disclose the information for the purposes laid out in the authorization and consent? Remote review is not “collecting” data; it is “reviewing” data. Also, redacting is super laborious, manual, and prone to errors.
-
Join this live, interactive webinar with guest presenters from the Duke Office of Clinical Research within the School of Medicine for ‘A Case for Sponsor Monitoring Remote Access to EMRs.’ This session presents how a successful program was implemented prior to COVID-19 and then leveraged during COVID-19 to support sponsor remote review of EMRs while maintaining control and security of the subjects’ data and maintaining subjects’ privacy based on the HIPAA authorization. Learn about a case example of a successful program implementation that avoids site burden and maintains attributability to records. Explore opportunities for sites and sponsors to find similar solutions. The webinar concludes with a question and answer session.
-
The FDA released new topics in the FAQ section of the guidance document for conducting clinical trials during the COVID-19 pandemic. The rapidly changing environment of the crisis has made it challenging to continue conducting and monitoring clinical trials in the traditional manner due to restrictions on travelling, dispensing investigational products, and social gathering. New questions continue to arise as the logistics of monitoring and conducting clinical trials become apparent.
